A pharmacokinetic study on formulation of adalimumab biosimilar (CHS-1420)

Trial Profile

A pharmacokinetic study on formulation of adalimumab biosimilar (CHS-1420)

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Mar 2017 New trial record
    • 13 Mar 2017 According to a Coherus Biosciences media release, company plans to initiate this study in the second-half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top